Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals

被引:11
作者
Chen, FD
Hsieh, BT
Wang, HE
Ou, YH
Yang, WK
Whang-Peng, J
Liu, RS
Knapp, FF
Ting, G
Yen, SH
机构
[1] Inst Nucl Energy Res, Atom Energy Council, Lungtan 32500, Taiwan
[2] Natl Yang Ming Univ, Fac Med Radiat Technol, Taipei 112, Taiwan
[3] Natl Yang Ming Univ, Inst Radiol Sci, Taipei 112, Taiwan
[4] Natl Hlth Res Inst, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Dept Nucl Med, Taipei, Taiwan
[6] Oak Ridge Natl Lab, Nucl Med Grp, Oak Ridge, TN USA
[7] Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan
关键词
re-188-sulfur colloid; melanoma; biodistribution; animal survival;
D O I
10.1016/S0969-8051(01)00244-X
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In this study, the effectiveness of a Re-188 labeled sulfur colloid with two particle size ranges was used to evalucate the effectiveness of this agent on melanoma tumors in mice in terms of animal lifespan. Methods: Two separate group of animals were used for investigating biodistribution and survival time. A total of 188 B16F10-melanoma-bearing BDF1 mice were injected intraperitoneally with 3.7 MBq (0.1 mCi)/2mL of radiolabeled sulfur colloid ten days after intraperitoneal inoculation of 5x10(5) B16F10 melanoma cells/2ml. For group 1, 30 mice were sacrificed at 1, 4, 24, 48 and 72 hours for biodistribution studies. In group 2, 158 mice were divided into 9 groups (n = 16 similar to 18/groups)each receiving respectively tumor alone, tumor with normal saline, cold colloid or hot colloid with 16, 23, 31, 46, 62, or 124 MBq activity. Each of these colloid groups was further divided into two groups, one receiving smaller particle sizes (<3<mu>m:80.4 +/- 7.2%, colloid 1) and the other receiving larger particle sizes (<3 <mu>m: 12.3 +/- 1.0%, colloid 2). The animals were checked daily until death and their survival recorded. Results: Colloid 2 showed higher accumulation in almost all tissues, the highest accumulation organ was tumor (similar to 40%), then spleen (-20%), stomach (-15%), diaphragm (-3%), and liver (-2%). There was a significant increase in survival time with increasing amount of the larger-particle-size colloid. Administered levels of 16-31 MBq/mouse were most efficacious and with higher amounts the survival times decreased significantly below that of the controls. There was a significant difference in the dose-response curves for the two preparations. Protection factors (1/Relative-risk) of nearly 5 were achieved using the larger colloid size, and nearly 30 using the smaller colloid size. An amount of 16-31 MBq of the colloid 2 was the optimal activity in these studies. On the one hand, the survival data agreed well with the biodistribution data, where higher accumulation was found in tumor with colloid 2. Conclusion: Rhenium-188 offers on-site availability, medium half-life, higher beta-particle energy of 2.12 MeV for therapy and emission of 155keV gamma photon suitable for imaging. The present study demonstrated that Re-188-sulfur colloid is an effective agent in controlling tumor cells in the abdominal cavity in animals. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:835 / 844
页数:10
相关论文
共 26 条
[11]  
HSIEH BT, 1996, NUCL SCI J, V23, P26
[12]  
KLINGENSMITH WC, 1983, J NUCL MED, V24, P8
[13]   PROCESSING OF REACTOR-PRODUCED W-188 FOR FABRICATION OF CLINICAL-SCALE ALUMINA-BASED W-188/RE-188 GENERATORS [J].
KNAPP, FF ;
CALLAHAN, AP ;
BEETS, AL ;
MIRZADEH, S ;
HSIEH, BT .
APPLIED RADIATION AND ISOTOPES, 1994, 45 (12) :1123-1128
[14]   Effect of reaction conditions on preparations of Rhenium-188 hydroxyethylidene diphosphonate complexes [J].
Lin, WY ;
Hsieh, JF ;
Lin, CP ;
Hsieh, BT ;
Ting, G ;
Wang, SJ ;
Knapp, FF .
NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (04) :455-459
[15]   RESIDENTS ESSAY AWARD - ALPHA-PARTICLE RADIO-IMMUNOTHERAPY - ANIMAL-MODELS AND CLINICAL PROSPECTS [J].
MACKLIS, RM ;
KAPLAN, WD ;
FERRARA, JLM ;
ATCHER, RW ;
HINES, JJ ;
BURAKOFF, SJ ;
COLEMAN, CN .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (06) :1377-1387
[16]  
Mathias CJ, 1998, J NUCL MED, V39, P1579
[17]  
Maxon HR, 1998, J NUCL MED, V39, P659
[18]   Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases [J].
Palmedo, H ;
Guhlke, S ;
Bender, H ;
Sartor, J ;
Schoeneich, G ;
Risse, J ;
Grünwald, F ;
Knapp, FF ;
Biersack, HJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (02) :123-130
[19]  
PATTILLO RA, 1995, J NUCL MED, V36, P29
[20]   THE DEVELOPMENT OF ALPHA-EMITTING RADIONUCLIDE LEAD 212 FOR THE POTENTIAL TREATMENT OF OVARIAN-CARCINOMA [J].
ROTMENSCH, J ;
ATCHER, RW ;
HINES, J ;
GRDINA, D ;
SCHWARTZ, JS ;
TOOHILL, M ;
HERBST, AL .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 160 (04) :789-797